Benefits of spironolactone as the optimal treatment for drug resistant hypertension. Pathway-2 trial review
| Image |  |
|---|---|
| Description | scientific article |
| Author/s | |
| Publication date | June 28, 2016 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |